| Name | Title | Contact Details |
|---|
VisionQuest Biomedical Inc. is a research and development company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets. VisionQuest has developed multiple medical devices with funding from the National Institutes of Health and is now looking to transfer those technologies to the commercial space. Our devices are currently being used in the United States and Latin America.
Seventh Sense Biosystems is a privately held medical technology company focused on developing innovative blood collection devices used in research and clinical testing. Our mission is to eliminate the barriers to successful blood sample collection and testing for health care professionals and consumers with simple, safe, mobile, and nearly painless technologies.
GeneCopoeia is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Modern lifestyles and persistent near vision utilization cause a majority of patients to experience the reduced visual acuity and painful symptoms of eye misalignment – headaches, eye strain, neck and shoulder pain, motion sickness and dry eye sensation. Neurolens addresses common binocular vision issues using a three-step process. Step one is efficiently identifying patient symptomology using a basic online symptom screener that every patient can complete in minutes. This information goes directly to the Neurolens Measurement Device, Gen 2—or NMD2—ready for step two, which is accurately and objectively measuring the patient`s level of misalignment. The NMD2 is an objective, accurate and repeatable way to measure eye misalignment as small as 0.01 Prism Diopters. Most importantly, step three is correcting eye misalignment with a proven lens solution. Neurolenses address binocular vision issues by providing a contoured prism lens design that gradually delivers more prism in the lens corridor from distance to near. Neurolenses are proven to have a profound impact on a patient`s visual clarity and comfort. In fact, 93% of patients responded positively to wearing Neurolenses. Over 81% of patients suffering from chronic daily headaches reported their symptoms were substantially reduced or basically gone after wearing Neurolenses for 90 days. Neurolens—recognized in 2022 as one of the 30 fastest growing private companies in the healthcare industry by Inc. Magazine—is confident that appropriately addressing growing binocular vision issues will become a standard of care in this industry, unlocking dramatic patient outcomes and practice growth.
Newport Medical Instruments, Inc. is a Costa Mesa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.